Research Article

Autologous Cytokine-Induced Killer Cell Immunotherapy Enhances Chemotherapy Efficacy against Multidrug-Resistant Tuberculosis

Table 5

Comparison for the main treatment indexes between CIK plus and chemo-mono groups after treatment 1 month and 3 months.

Clinical syndromesTreatment 1 monthTreatment 3 months
CIK plusChemo-mono valueCIK plusChemo-mono value

Cough (, %)0, 0.09, 100.00<0.0010, 0.08, 88.9<0.001
Expectoration (, %)0, 0.05, 55.60.0292, 22.29, 100.00.029
Hemoptysis (, %)0, 0.00, 0.010, 0.01, 11.11
Chest pain (, %)0, 0.01, 11.110, 0.00, 0.01
Dyspnea (, %)3, 33.35, 55.60.6373, 33.35, 55.60.637
Fatigue (, %)1, 11.13, 33.30.6371, 11.13, 33.30.637
Fever (, %)1, 11.10, 0.011, 11.10, 0.01
Sputum smear test (, %)1, 11.19, 100.00<0.0011, 11.17, 77.80.015
Sputum culture (, %)1, 11.17, 77.80.0150, 0.04, 44.40.082
Right upper lobe (, %)7, 77.88, 88.917, 77.88, 88.91
Right middle lobe (, %)6, 66.78, 88.90.5776, 66.79, 100.00.206
Right lower lobe (, %)9, 100.05, 55.60.0829, 0.05, 55.60.082
Left upper lobe (, %)8, 88.98, 88.918, 88.98, 88.91
Left lower lobe (, %)4, 44.47, 77.80.3354, 44.47, 77.80.335
Improvement in the right upper lobe (yes, %)3, 33.30, 0.00.2063, 33.31, 11.10.577
Improvement in the right middle lobe (yes, %)1, 11.10, 0.011, 11.10, 0.01
Improvement in the right lower lobe (yes, %)2, 22.20, 0.00.4716, 66.70, 0.00.009
Improvement in the left upper lobe (yes, %)3, 33.30, 0.00.2064, 44.40, 0.00.082
Improvement in the left lower lobe (yes, %)1, 11.10, 0.011, 11.10, 0.01

means score 2 or 3; the other means score 0 or 1. Criteria for evaluation and score are in Table 2.